#### STATUS OF THE CLAIMS

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

Claims 1, 9 and 11-13 are examined in the present office action.

# 1. (Previously Presented) A reaction mixture, comprising:

- a) a first oligonucleotide primer comprising i) a T7 promoter sequence, ii) a ribosome binding site sequence, iii) a start codon, iv) a sequence coding for a first epitope marker,
- v) a sequence coding for a second epitope marker, and vi) a first region of complementarity to a region of a gene of interest; and
- b) a second oligonucleotide primer comprising i) at least one stop codon, and ii) a sequence encoding for a third epitope marker, wherein said first and second epitope markers are selected from the group consisting of SEQ ID NOS: 5, 6, 7, 8 and 9, and wherein said first and second epitope markers are different.

### 2-8. (Canceled)

### 9. (Previously Presented) A kit, comprising:

- a) a first oligonucleotide primer comprising i) a T7 promoter sequence, ii) a ribosome binding site sequence, iii) a start codon, iv) a sequence coding for a first epitope marker,
- v) a sequence coding for a second epitope marker, and vi) a first region of complementarity to a region of the APC gene;
- b) a second oligonucleotide primer comprising i) at least one stop codon, and ii) a sequence encoding for a third epitope marker, wherein said first and second epitope markers are selected from the group consisting of SEQ ID NOS: 5, 6, 7, 8 and 9, and wherein said first and second epitope markers are different;
- c) a microtiter plate coated with a ligand capable of binding to said second epitope marker;
- d) a first antibody capable of binding to said first epitope marker; and
- e) a second antibody capable of binding to said third epitope marker.

# 10. (Canceled)

- 11. (Previously Presented) The kit of Claim 9, wherein said second oligonucleotide primer further comprises iii) a second region of complementarity to a template.
- 12. (Previously Presented) The kit of Claim 9, wherein said first region of complementarity is greater than 15 bases in length.
- 13. (Previously Presented) The kit of Claim 11, wherein said second region of complementarity is greater than 15 bases in length.

14-37. (Canceled)